Editorial: Extracellular Vesicle Treatment, Epigenetic Modification and Cell Reprogramming to Promote Bone and Cartilage Regeneration

Yixuan Amy Pei¹, Yufeng Dong², Tong-Chuan He³, Wan-Ju Li⁴, Wei Seong Toh⁵,⁶ and Ming Pei¹*

¹ Stem Cell and Tissue Engineering Laboratory, Department of Orthopaedics, West Virginia University, Morgantown, WV, United States, ² Department of Orthopedic Surgery, Center for Tissue Engineering and Regenerative Medicine, Louisiana State University Health Sciences Center, Shreveport, LA, United States, ³ Molecular Oncology Laboratory, Department of Orthopaedic Surgery and Rehabilitation Medicine, The University of Chicago Medical Center, Chicago, IL, United States, ⁴ Department of Orthopedics and Rehabilitation, University of Wisconsin-Madison, Madison, WI, United States, ⁵ Faculty of Dentistry, National University of Singapore, Singapore, Singapore, ⁶ Department of Orthopaedic Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

Keywords: extracellular vesicle, decellularized extracellular matrix, cell reprogramming, bone regeneration, cartilage regeneration, cell sheet, tissue engineering

Editorial on the Research Topic

Extracellular Vesicle Treatment, Epigenetic Modification and Cell Reprogramming to Promote Bone and Cartilage Regeneration

Trauma, tumor, and age-related degeneration can damage bone and cartilage beyond a critical point, resulting in bone loss, cartilage defects, and osteoarthritis if left untreated. Traditional bone transplantation relies on autografts and allografts, which are limited in availability and have poor clinical efficacy due to donor site morbidity, immune issues, disease transmission, and unpredictable autologous resorption (Betz, 2002; Benic and Hämmerle, 2014). Similarly, cartilage restoration techniques like autologous chondrocyte implantation, osteochondral transplantation, and microfracture often lead to fibrotic scar tissue formation, which can cause pain and which have inconsistent long-term results (Valderrabano et al., 2009; Levy et al., 2013). Recent advances have recognized innovative approaches in enhancing bone and cartilage regeneration after injury.

The wide array of treatment options used to support the body’s regenerative abilities ranges from scaffold enhancement (Qasim et al., 2019) to extracellular vesicle (EV)-based therapies (Toh et al., 2014; Negoro et al., 2018).

Although cell sheet technology has been widely used in tissue engineering (Imashiro and Shimizu, 2021), Xu et al., found that in vitro high-density cultures trigger human bone marrow-derived mesenchymal stem cells (BMSCs) to undergo spontaneous cell senescence with a gradually increasing inflammatory profile and a build-up of reactive oxygen species. This finding is in line with a previous report, in which human synovium-derived stem cells (SDSCs), which contributed to the deposition of extracellular matrix (cell sheet), exhibited a significantly decreased chondrogenic potential (Zhang et al., 2015). Xu et al., also found that this effect was reduced in Wnt3a-treated cells, as Wnt signaling is thought to activate cell cycle inhibitor p27, redirecting cells into quiescence instead of senescence, which provides a solution to generating multiple layer cell sheets with mitigated cell senescence.
Bone substitutes, which are engineered and implanted into the body to support tissue remodeling, are popular alternatives to autografts and allografts. This regenerative technique replicates the natural bone microenvironment by combining biomaterial scaffolds with growth factors and progenitor cells, thus providing a site onto which cells can attach, spread, migrate, proliferate, and differentiate. Zhang et al., reviewed various scaffold biomaterials, including inorganic compound-based ceramics, organic natural polymers, and synthetic polymers, which can be used in bone tissue engineering. Depending on the composition, biomaterials vary in effectiveness across the categories of biocompatibility, biodegradability, osteoconductivity, osteoinductivity, and mechanical properties. Interestingly, tissue-derived decellularized extracellular matrix (T-DECM) attracted more attention due to its mimicking of the complex microenvironment of native bone tissues.

Compared to bone, cartilage is known to be more difficult to regenerate due to its avascular nature, low chondrocyte proliferative ability, low progenitor cell count, and slow matrix turnover. Zhao et al., summarized the different natural and synthetic polymer scaffold biomaterials used in cartilage engineering. Along with the use of T-DECM, scaffold-based 3D bioprinting techniques including laser technology, extrusion, and jetting, are capable of mimicking the native tissue environment by delivering live cells and their corresponding scaffolding material in a precise and customizable manner. T-DECM has been recognized as a natural scaffold for engineering tissue; intriguingly, cell-derived dECM (C-DECM) acts differently by providing an in vitro microenvironment for the rejuvenation of primary cells and MSCs in proliferation and differentiation capacity for cartilage regeneration (Sun et al., 2018).

Outside of these commonly used biomaterials, a new composite scaffold, tannin, has been proposed by Yang and Abdalla. Resembling ceramic, porous tannin spray-dried powder (PTSDP) has considerable potential for use in bone graft engineering. They found that the macroporosity of tannin enhanced scaffolds was maintained by controlling the number and diameter of polyethylene glycol particles, thus enhancing infiltration, communication, and growth of human induced pluripotent stem cell-derived mesenchymal progenitors to better mimic the bone microenvironment. The study also found that these PTSDP scaffolds support long-term viability, attachment, and osteogenic differentiation.

Besides scaffold enhancement, there has also been increasing interest in incorporating cellular components with endogenous therapeutic capability into tissue regeneration. Hypoxia inducible factor-1α (HIF-1α) is known to be integral to bone defect repair, but it is typically unstable under normoxic conditions. Ying et al., found that mutant HIF-1α (a stabilized version of HIF-1α) stimulated rat BMSCs’ proliferation and osteogenic differentiation in culture. Furthermore, in vivo studies demonstrated that mutant HIF-1α applied to a porous β-TCP scaffold promoted bone regeneration and neovascularization in mouse cranial defects 12 weeks post-surgery.

There is increasing evidence supporting the use of EVs from MSCs as a therapeutic device, as the wide array of components such as mRNA, miRNA, lipids, and bioactive proteins within the vesicles serve as mediators of intercellular communication and can promote wide-ranging tissue repair and regeneration, including cartilage repair (Toh et al., 2017). To et al., conducted a systematic review of 10 case-control in vivo studies looking at 159 murine subjects and found that the surgical application of human MSC-derived EVs reduced cartilage loss in cartilage injury sites. These EVs represent a cell-free option for cartilage repair that avoids the many risks of cell-based therapies, such as metastasis. Cumulatively, these studies indicate that EVs are capable of impacting various signaling pathways in many different cell types, not only directly promoting chondrogenesis but also decreasing macrophage-induced inflammation to support cartilage repair. Given that these studies use different EV isolation methods, animal models, and dosing regimens, future studies with better standardization are required.

As the authors explore new avenues of skeletal tissue regeneration, the future of tissue bioengineering can be seen heading in the direction of personalized medicine. Scaffold enhancement has become a widespread method to incorporate different factors that can more fully mimic the physiological function and architecture of bone tissue. Given the promise of EVs in therapeutic applications, it is important to recognize the epigenetic roots that underlie bone and cartilage degeneration (Van Meurs et al., 2019) and the potential use of chemicals and pharmaceuticals to promote the desired epigenetic modifications that drive chondrogenic and osteogenic differentiation in scaffolds (Eslaminejad et al., 2013). Indeed, EVs have potential to serve as vehicles for drug and molecule delivery to support skeletal tissue regeneration. However, despite the therapeutic potential of these new therapies, we must be cautious of the uncertain impact that these foreign substances may have on endogenous signaling pathways and the long-term robustness of the repair tissue. Any safety risks associated with these new technologies must also be fully scrutinized before they are translated into clinical applications.

**AUTHOR CONTRIBUTIONS**

YAP performed the collection and assembly of data, data analysis and interpretation, manuscript writing, and final approval. YD, TCH, W-JL, and WST performed data analysis and interpretation as well as final approval. MP performed conception and design, data analysis and interpretation, manuscript writing and final approval, and financial support. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was partially supported by a Research Grant from the National Institutes of Health (AR067747).

**ACKNOWLEDGMENTS**

We thank Suzanne Danley for editing the manuscript.
REFERENCES

Benic, G. I., and Hämmerle, C. H. (2014). Horizontal bone augmentation by means of guided bone regeneration. Periodontol. 2000 66, 13–40. doi: 10.1111/prd.12039

Betz, R. R. (2002). Limitations of autograft and allograft: new synthetic solutions. Orthopedics 25, S561–S570. doi: 10.3928/0147-7447-20020502-04

Eslaminejad, M. B., Fani, N., and Shahhoseini, M. (2013). Epigenetic regulation of osteogenic and chondrogenic differentiation of mesenchymal stem cells in culture. Cell J. 15, 1–10.

Imashiro, C., and Shimizu, T. (2021). Fundamental technologies and recent advances of cell-sheet-based tissue engineering. Int. J. Mol. Sci. 22:425. doi: 10.3390/ijms22010425

Levy, Y. D., Görtz, S., Pulido, P. A., McCauley, J. C., and Bugbee, W. D. (2013). Do fresh osteochondral allografts successfully treat femoral condyle lesions? Clin. Orthop. Relat. Res. 471, 231–237. doi: 10.1007/s11999-012-2556-4

Negoro, T., Takagaki, Y., Okura, H., and Matsuyama, A. (2018). Trends in clinical trials for articular cartilage repair by cell therapy. NPJ Regen. Med. 3:17. doi: 10.1038/s41536-018-0055-2

Qasim, M., Chae, D. S., and Lee, N. Y. (2019). Advancements and frontiers in nano-based 3D and 4D scaffolds for bone and cartilage tissue engineering. Int. J. Nanomed. 14, 4333–4351. doi: 10.2147/IJN.S209431

Sun, Y., Yan, L. Q., Chen, S., and Pei, M. (2018). Functionality of decellularized matrix in cartilage regeneration: a comparison of tissue versus cell sources. Acta Biomater. 74, 56–73. doi: 10.1016/j.actbio.2018.04.048

Toh, W. S., Foldager, C. B., Pei, M., and Hui, J. H. (2014). Advances in mesenchymal stem cell-based strategies for cartilage repair and regeneration. Stem Cell Rev. Rep. 10, 686–696. doi: 10.1007/s12015-014-9526-z

Toh, W. S., Lai, R. C., Hui, J. H. P., and Lim, S. K. (2017). MSC exosome as a cell-free MSC therapy for cartilage regeneration: implications for osteoarthritis treatment. Semin. Cell Dev. Biol. 67, 56–64. doi: 10.1016/j.semcdb.2016.11.008

Valderrabano, V., Leumann, A., Rasch, H., Egelhof, T., Hintermann, B., and Pagenstert, G. (2009). Knee-to-ankle mosaicplasty for the treatment of osteochondral lesions of the ankle joint. Am. J. Sports Med. 37, 105S–111S. doi: 10.1177/0363546509351481

Van Meurs, J. B., Boer, C. G., Lopez-Delgado, L., and Riancho, J. A. (2019). Role of epigenomics in bone and cartilage disease. J. Bone Miner. Res. 34, 215–230. doi: 10.1002/jbmr.3662

Zhang, Y., Li, J. T., Davis, M. E., and Pei, M. (2015). Delineation of in vitro chondrogenesis of human synovial stem cells following preconditioning using decellularized matrix. Acta Biomaterialia 20, 39–50. doi: 10.1016/j.actbio.2015.04.001

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Pei, Dong, He, Li, Toh and Pei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.